for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

DAIICHI SANKYO COMPANY, LIMITED

4568.T

Latest Trade

6,632.00JPY

Change

-182.00(-2.67%)

Volume

1,329,100

Today's Range

6,632.00

 - 

6,767.00

52 Week Range

3,277.00

 - 

7,358.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Daiichi Sankyo Receives Negative CHMP Opinion For Quizartinib For Treatment Of Patients With Relapsed/Refractory FLT3-ITD AML

Oct 18 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO RECEIVES NEGATIVE CHMP OPINION FOR FLT3 INHIBITOR QUIZARTINIB FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY FLT3-ITD AML.DAIICHI SANKYO CO LTD - GLOBAL CLINICAL DEVELOPMENT PROGRAM OF QUIZARTINIB CONTINUES.DAIICHI SANKYO - TO EVALUATE CHMP FEEDBACK TO DETERMINE NEXT STEPS FOR QUIZARTINIB FOR TREATING PATIENTS WITH RELAPSED/REFRACTORY FLT3-ITD AML IN EUROPE.

EMA Says CHMP Recommends Conditional Marketing Authorisation For Ebola Vaccine Ervebo

Oct 18 (Reuters) - European Medicines Agency::CHMP RECOMMENDS GRANTING CONDITIONAL MARKETING AUTHORISATION FOR ERVEBO FOR ACTIVE IMMUNISATION OF PEOPLE ABOVE 18 YEARS AT RISK OF EBOLA VIRUS.CHMP ADOPTED NEGATIVE OPINION FOR VANFLYTA (QUIZARTINIB); VANFLYTA WAS EXPECTED TO BE USED TO TREAT ADULTS WITH ACUTE MYELOID LEUKAEMIA.CHMP RECOMMENDED GRANTING A MARKETING AUTHORISATION FOR BAQSIMI (GLUCAGON), TREATMENT FOR SEVERE HYPOGLYCAEMIA .QUOFENIX (DELAFLOXACIN) RECEIVED A POSITIVE OPINION FROM CHMP FOR TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS.SPRAVATO (ESKETAMINE) GOT POSITIVE OPINION FROM CHMP FOR COMBINATION TREATMENT IN ADULTS WITH TREATMENT-RESISTANT MAJOR DEPRESSIVE DISORDER.CHMP RECOMMENDED GRANTING A MARKETING AUTHORISATION FOR RINVOQ (UPADACITINIB) FOR TREATMENT OF RHEUMATOID ARTHRITIS .CHMP ADOPTED A NEGATIVE OPINION RECOMMENDING REFUSAL OF A MARKETING AUTHORISATION FOR HOPVEUS (SODIUM OXYBATE).CHMP RE-EXAMINED INITIAL OPINIONS FOR REVOLADE (ELTROMBOPAG) AND TRANSLARNA (ATALUREN) AND CONFIRMED PREVIOUS RECOMMENDATIONS .

Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) In Japan With Regulatory Submission In Her2 Positive Metastatic Breast Cancer

Sept 9 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO - ADVANCES FAM- TRASTUZUMAB DERUXTECAN (DS-8201) IN JAPAN WITH REGULATORY SUBMISSION IN HER2 POSITIVE METASTATIC BREAST CANCER.

Daiichi Sankyo Says U.S. FDA Approved Co's Turalio For Treatment Of Select Patients With TGCT, A Rare And Debilitating Tumor

Aug 5 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::FDA APPROVES DAIICHI SANKYO'S TURALIO™ (PEXIDARTINIB) FOR THE TREATMENT OF SELECT PATIENTS WITH TGCT, A RARE AND DEBILITATING TUMOR.DAIICHI SANKYO CO - TURALIO IS APPROVED WITH A BOXED WARNING FOR HEPATOTOXICITY DUE TO THE RISK OF SERIOUS AND POTENTIALLY FATAL LIVER INJURY.DAIICHI SANKYO - FDA APPROVAL OF TURALIO BASED ON RESULTS OF PIVOTAL PHASE 3 ENLIVEN STUDY.DAIICHI SANKYO - TURALIO IS THE SECOND OF SEVEN NEW PRODUCTS THAT DAIICHI SANKYO IS COMMITTED TO DELIVERING FROM ITS ONCOLOGY PIPELINE BY 2025.

FDA Approves Daiichi Sankyo's Turalio For Treatment Of Select Patients With TGCT, A Rare And Debilitating Tumor

Aug 2 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::FDA APPROVES DAIICHI SANKYO'S TURALIO™ (PEXIDARTINIB) FOR THE TREATMENT OF SELECT PATIENTS WITH TGCT, A RARE AND DEBILITATING TUMOR.DAIICHI SANKYO- FDA APPROVES DAIICHI SANKYO'S TURALIO™ (PEXIDARTINIB) FOR TREATMENT OF SELECT PATIENTS WITH TGCT, A RARE AND DEBILITATING TUMOR.

FDA Approves First Therapy For Rare Joint Tumor

Aug 2 (Reuters) - FDA::FDA APPROVES FIRST THERAPY FOR RARE JOINT TUMOR.FDA - GRANTED APPROVAL OF TURALIO TO DAIICHI SANKYO.

American Regent Announces Launch And Availability Of Selenious Acid Injection, USP

July 10 (Reuters) - American Regent Inc::AMERICAN REGENT INC - ANNOUNCES LAUNCH AND AVAILABILITY OF SELENIOUS ACID INJECTION, USP; PRODUCT IS AVAILABLE FOR IMMEDIATE SHIPMENT.

Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML

June 21 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO PROVIDES UPDATE ON FDA REVIEW OF QUIZARTINIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY FLT3-ITD AML.DAIICHI SANKYO CO LTD - RECEIVED A COMPLETE RESPONSE LETTER (CRL) FROM U.S. FOOD AND DRUG ADMINISTRATION (FDA.DAIICHI SANKYO CO LTD - RECEIVED CRL FOR (NDA) OF QUIZARTINIB FOR TREATMENT OF ADULTS WITH RELAPSED/REFRACTORY FLT3-ITD ACUTE MYELOID LEUKEMIA (AML)..

Daiichi Sankyo Co Ltd - Not True It Is Negotiating Sale Of Otc Drug Business

May 23 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO CO LTD - NOT TRUE IT IS NEGOTIATING SALE OF OTC DRUG BUSINESS.

Daiichi Sankyo Provides Update On Ongoing FDA Review For Quizartinib For Treatment Of Patients With Relapsed/Refractory FLT3-ITD AML

April 4 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO PROVIDES UPDATE ON ONGOING FDA REVIEW FOR QUIZARTINIB FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY FLT3-ITD AML.DAIICHI SANKYO CO LTD - NEW PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE IS AUGUST 25, 2019..DAIICHI SANKYO - FDA EXTENDED ACTION DATE TO ALLOW TIME TO REVIEW ADDITIONAL DATA SUBMITTED BY DAIICHI SANKYO IN ASSOCIATION WITH AN FDA REQUEST..

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up